Viridian Therapeutics, Inc.\DE
VRDN
DELAYED 1 MONTH
12 insider filings · Latest: May 11, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | May 13 8:31 PM | Fairmount Funds Management LLCDirector, 10% Owner | Purchase | 1,176,470 | $17.00 | $20.0M | 5,090,928(I) | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026 | Mar 5 12:17 AM | Jennifer TousignantChief Legal Officer | Option Exercise | 5,169 | — | 15,510(D) | View → |
| Mar 2, 2026 | Mar 5 12:17 AM | Jennifer TousignantChief Legal Officer | Grant/Award | 143,150 | $30.25 | 23,850(D) | View → |
| Mar 3, 2026 | Mar 5 12:15 AM | Seth HarmonChief Financial Officer | Option Exercise | 6,267 | — | 18,801(D) | View → |
| Mar 2, 2026 | Mar 5 12:15 AM | Seth HarmonChief Financial Officer | Grant/Award | 123,400 | $30.25 | 20,550(D) | View → |
| Mar 3, 2026 | Mar 4 11:58 PM | Thomas W. BeethamChief Operating Officer | Option Exercise | 9,409 | — | 28,227(D) | View → |
| Mar 2, 2026 | Mar 4 11:58 PM | Thomas W. BeethamChief Operating Officer | Grant/Award | 211,850 | $30.25 | 35,300(D) | View → |
| Mar 3, 2026 | Mar 4 11:56 PM | Stephen F. MahoneyPresident and CEO | Option Exercise | 18,357 | — | 55,071(D) | View → |
| Mar 2, 2026 | Mar 4 11:56 PM | Stephen F. MahoneyPresident and CEO | Grant/Award | 671,500 | $30.25 | 111,900(D) | View → |
| Mar 2, 2026 | Mar 4 11:51 PM | Radhika TripuraneniChief Medical Officer | Grant/Award | 114,950 | $30.25 | 19,150(D) | View → |